Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Study 201312: Long-term mepolizumab treatment in life-threatening or seriously debilitating asthma
2014-000314-54Phase 3Completed
- Sponsor
- GSK
- Start
- Mar 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of mepolizumab in severe asthma, sponsored by GSK. Primary endpoint: Annualized rate of exacerbations. Started Mar 2014; status: completed.
02
Drugs
mepolizumab
03
Conditions
severe asthma
Beyond the preview
Go deeper on 2014-000314-54.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-000314-54.